Upload
others
View
8
Download
0
Embed Size (px)
Citation preview
PUTTING PATIENTS AT THE CENTRE OF HEALTHCARE #ARCSAUS
C26: Shared Investigator Platform (SIP) Overview
Speaker: Toni Hopkins, MSD
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved. 2
Our Shared Vision:
To improve the health of people around
the world by accelerating and simplifying
the research and development of
innovative new therapies.
TransCelerate:
A Not-for-Profit Entity Created to Foster Collaboration
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
2 0 MEMBER
COMPANIES
Current state of organization
Today
25+including 4
pharmacovigilance initiatives
INITIATIVES
focus on preclinical research
ENHANCING INDUSTRY
COLLABORATION
With an effective and
proven governance
structure have increased the
ease and desire to collaborate
FACILITATING
FUTURE PLATFORM TRIALS
12+ initiatives deliver solutions that facilitate future platform
trials
BREADTH &
DEPTH
Over 30 solutions
being delivered across 25+
initiatives, across 3
strategic priorities
TransCelerate Founded
2012
5 INITIAL
INITIATIVES
10 MEMBER
COMPANIES
3
platform to enable data sharing
BioCelerate Founded
2016
Regeneron most recent member
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
The Reach of our Global Membership is Expanding
4
There are
over
peoplefrom Member Companies that
design and develop
TransCelerate solutions.
Membership is available to biopharmaceutical research and development organizations
that engage in innovative discovery, development and manufacturing of new medicines*.
* to be eligible for membership, companies must meet
specified eligibility criteria.
SIP Concept
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Moving the Needle: TransCelerate Initiatives
6
Reduce the burden on investigative sites
by providing them with a central point
of access, harmonized content and services, and streamlined interaction
with participating clinical trial Sponsors.
Establish a voluntary registry for consenting investigators. Providing a
global collaborative image that will be
beneficial for clinical trial efficiency and
productivity.
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
SIP Vision
7
Ce
ntr
al Po
int
of
Ac
ce
ssH
arm
on
ize
d C
on
ten
t
Reuse of Data
SIP Functionality
and Benefits
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
SIP Delivered Roadmap
9
The Shared Investigator Platform - developed With Sites, For Sites
Release 1(Jan 2016)
✓ Single Sign On
✓ User Profile
✓ Facility Profile
✓ Training
✓ Feasibility Surveys
✓ Study Workspace
✓ Document Exchange
✓ Tasks, Alerts & Notifications
✓ Dashboards and Reporting
Release 2(Aug 2017)
✓ Document Management (e.g., versioning, workflow, e-signatures, Integration to sponsor eTMF
✓ Safety Letters
✓ Enhanced functionality
✓ Expanded Reporting
✓ Usability enhancements
Release 3(Mar 2019)
✓ Enable Onboarding at Scale
✓ Migration ongoing studies
✓ Bulk registration
✓ Centralized Workflows
✓ Site Networks, Large Univ/Hospitals, SMO, ARO
✓ Investigator Payments
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Pre-Study Selection Benefits: Single sign-on, Re-use of
Site User Profiles Information
10
Process
without SIP
Process
with SIP
Log onto multiple portals
with varying processes for
different Sponsors
Completion of CV
information in various
formats for each Sponsor
Log onto one Platform to
collaborate in a harmonized way
with participating Sponsors
Benefit: Complete User Profile once
and maintain to auto-generate a
standardized CV and reuse for
producing an e-1572
~1-2 hours to complete the User Profile and enable re-use across Platform
Several hours to provide redundant profile information for each study and Sponsor
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Facility profile
▪ Do you have a -70° freezer?
▪ How long are your IRB turnaround times?
▪ Do you have a monitoring system for cold
storage?
▪ How frequently does your IRB meet?
▪ Do you have an X-ray?
▪ …..
50% less
questions
Feasibility survey
8 Number of Calendar Days, on average, a feasibility survey is
completed, shortening Site ID Timelines
Re-use of Facility Profile data to streamline completion
of Feasibility Survey and Study Site details
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Today – Combined Solution Value to Investigators
Your
Colleagues
are Realizing
this Value!
PROFILE
DATA
TRANSPARENCY
ACCESS
DATA TRANSPARENCY
Investigators can add a comment to a study
record to put the enrollment metrics into context from a defined
set of options
Showing investigators their own data
demystifies what data is being shared
Investigator can create, view their own study history across sponsors, including enrollment metrics, and edit profile
Expand access to research opportunities by making investigators/sites known to more sponsors
ACCESS
PROFILE
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Today – What Sites are Saying
“SIP is the right way in leading sponsors and
investigators to work together on important,
required steps in the set up process, which results in less paperwork and less
unnecessary / duplicate steps in their
collaboration with various sponsors, and
most importantly, more time for the
patients.”- Investigator in Greece
“I had a very positive experience with
setting up my profile and answering the
surveys in SIP. I believe this is the future way
of working.”- Investigator in France
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Today – We Hear You – Re-Use of Information
How SIP meets your requests:
• Sites can re-use their Facility
Profile information to pre-
populate parts of the
Feasibility Survey, reducing
time needed to complete
the survey
• Investigators can delegate
the completion of Feasibility
Surveys to central offices of
Site Networks, AROs, and
SMOs, while having the ability to directly review and make
changes to their information.
Feasibility is taking
way too much time–
we need a way to
reuse our
information, but also
to use the central
office to manage
feasibility surveys on
our behalf.
-Sites
Once SIP supports our
ability to receive these
types of contacts
(invitations, surveys, etc)
on investigators’ behalf,
we’ll be able to help them
conduct their studies in
the system.
-Site Network Organization
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Post- Study Selection Benefits: Mutual Recognition
Training (MRT) Program
15
Process
without SIP
Process
with SIP
Investigator must complete GCP
Training for each Sponsor
Site User submits MRT
Request to Sponsor
Sponsor can accept
MRT request
Site User may receive GCP Training Credit
without having to repeat training
Site User completes a GCP Training
under MRT Program
Sponsor 1 Sponsor 2 Sponsor 3
Training
Certificate
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Value Proposition
16
Reduce risk
with Site as
source of
info
Improved
relationships
Globalize
processes Save time
and effort
Active
listening and
responding
Harmonizatio
n of delivery
of content
and services
Reduce
administrative
burden and
duplication
Recognized as
a leader and
innovator in
the industry
SPONSORS
SITES
Current SIP
Journey and
Implementation
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
Current Global Usage
18
❖ 6 Sponsors are live on the Platform
❖ 28,695 Registered Site Users
❖ 10,940 Sponsor Users
❖ 81 Countries
❖ 269 Studies Created
❖ 1,008 Site Personnel >1 Study
❖ 91 Investigators > 1 Sponsor
*as of 29 July 2019
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
SIP Adoption—Australia
19
Oceania 758
American Samoa 1
Australia 584
New Zealand 173
*as of 29 July 2019
SIP Registered Site Users in Oceania Region
Copyright ©2018 TransCelerate BioPharma Inc., All rights reserved.
SIP Journey
20
Q1 2016SIP Release 1.01st Member Company Adoption
Q4 2016 – Q1 2017Releases 1.1 – 1.32nd and 3rd Member Company Adoptions
Q3 2017 – Q1 2018Releases 2.0 and 2.14th Member Company Adoption
Q3 2018- Q1 2019Releases 3.0- 3.12 Additional Member Company Adoptions expected.SIP Core Product Requirements are fulfilled.5th Member Company Adoption
Q2-Q3 2019Implementation of Governance strategy and transition plan. 6th Member Company Adoption
Q4 2019
Release 4.0
SIP User Group Launched
2020 and beyondTransition is complete and Cognizant is the sole owner of SIP.
Thank you